|
1
|
Bruix J, Gores GJ and Mazzaferro V:
Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut.
63:844–855. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Lu R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the asia-pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ikeda M, Mitsunaga S, Shimizu S, Ohno I,
Takahashi H, Okuyama H, Kuwahara A, Kondo S, Morizane C, Ueno H, et
al: Efficacy of sorafenib in patients with hepatocellular carcinoma
refractory to transcatheter arterial chemoembolization. J
Gastroenterol. 49:932–940. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ogasawara S, Chiba T, Ooka Y, Kanogawa N,
Motoyama T, Suzuki E, Tawada A, Kanai F, Yoshikawa M and Yokosuka
O: Efficacy of sorafenib in intermediate-stage hepatocellular
carcinoma patients refractory to transarterial chemoembolization.
Oncology. 87:330–341. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Arizumi T, Ueshima K, Minami T, Kono M,
Chishina H, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, et al:
Effectiveness of sorafenib in patients with transcatheter arterial
chemoembolization (TACE) refractory and intermediate-stage
hepatocellular carcinoma. Liver Cancer. 4:253–262. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kudo M, Imanaka K, Chida N, Nakachi K, Tak
WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, et al: Phase
III study of sorafenib after transarterial chemoembolization in
Japanese and Korean patients with unresectable hepatocellular
carcinoma. Eur J Cancer. 47:2117–2127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lencioni R, Llovet JM, Han G, Tak WY, Yang
J, Guglielmi A, Paik SW, Reig M, Kim DY, Chau GY, et al: Sorafenib
or placebo plus TACE with doxorubicin-eluting beads for
intermediate stage HCC: The SPACE trial. J Hepatol. 64:1090–1098.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ohki T, Sato K, Yamagami M, Ito D, Yamada
T, Kawanishi K, Kojima K, Seki M, Toda N and Tagawa K: Efficacy of
transcatheter arterial chemoembolization followed by sorafenib for
intermediate/advanced hepatocellular carcinoma in patients in
Japan: A retrospective analysis. Clin Drug Investig. 35:751–759.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ohki T, Sato K, Yamagami M, Ito D, Yamada
T, Kawanishi K, Kojima K, Seki M, Toda N and Tagawa K: Erratum to:
Efficacy of transcatheter arterial chemoembolization followed by
sorafenib for intermediate/advanced hepatocellular carcinoma in
patients in Japan: A retrospective analysis. Clin Drug Investig.
36:93–96. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bruix J, Qin S, Merle P, Granito A, Huang
YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, et al:
Regorafenib for patients with hepatocellular carcinoma who
progressed on sorafenib treatment (RESORCE): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet. 389:56–66.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ogasawara S, Chiba T, Ooka Y, Suzuki E,
Maeda T, Yokoyama M, Wakamatsu T, Inoue M, Saito T, Kobayashi K, et
al: Characteristics of patients with sorafenib-treated advanced
hepatocellular carcinoma eligible for second-line treatment. Invest
New Drugs. 36:332–339. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lencioni R and Llovet JM: Modified RECIST
(mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis.
30:52–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Uchikawa S, Kawaoka T, Aikata H, Kodama K,
Nishida Y, Inagaki Y, Hatooka M, Morio K, Nakahara T, Murakami E,
et al: Clinical outcomes of sorafenib treatment failure for
advanced hepatocellular carcinoma and candidates for regorafenib
treatment in real-world practice. Hepatol Res. 48:814–820. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kuzuya T, Ishigami M, Ishizu Y, Honda T,
Hayashi K, Ishikawa T, Nakano I, Hirooka Y and Goto H: Prognostic
factors associated with postprogression survival in advanced
hepatocellular carcinoma patients treated with sorafenib not
eligible for second-line regorafenib treatment. Oncology. 95:91–99.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kanda Y: Investigation of freely-available
easy-to use software ‘EZR’ for medial statistics. Bone Marrow
Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
The general rules for the clinical and
pathological study of primary liver cancer study group of japan.
Liver cancer study group of Japan. Jpn J Surg. 19:98–129. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takeda H, Nishikawa H, Iguchi E, Ohara Y,
Sakamoto A, Hatamaru K, Henmi S, Saito S, Nasu A, Komekado H, et
al: Impact of pretreatment cholinesterase level in unresectable
advanced hepatocellular carcinoma patients treated with sorafenib.
Mol Clin Oncol. 1:241–248. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
European association for the study of the
liver electronic address, . simpleEasloffice@easloffice.eu;
European association for the study of the liver: EASL clinical
practice guideline: Management of hepatocellular carcinoma. J
Hepatol. 69:182–236. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Brux J and Shernman M; American
association for the study of liver disease, : Management of
hepatocellular carcinoma: An update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Heimbach JK, Kulil LM, Finn RS, Sirlin CB,
Abecassis MM, Roberts LR, Zhu AX, Murad MH and Marrero JA: AASLD
guidelines for treatment of hepatocellular carcinoma. Hepatology.
67:358–380. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Verslype C, Rosmorduc O and Rougier P;
ESMO Guidelines Working Group, : Hepatocellular carcinoma:
ESMO-ESDO clinical practice guideline for diagnosis, treatment and
follow-up. Ann Oncol. 23 (Suppl 7):vii41–vii48. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kudo M, Matsui O, Izumi N, Iijima H,
Kadoya M, Imai Y, Okusaka T, Miyayama S, Tsuchiya K, Ueshima K, et
al: JSH consensus-based clinical practice guidelines for the
management of hepatocellular carcinoma: 2014 update by the liver
cancer study group of Japan. Liver Cancer. 3:458–468. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Terashima T, Yamashita T, Horii R, Arai K,
Kawaguchi K, Kitamura K, Yamashita T, Sakai Y, Mizukoshi E, Honda M
and Kaneko S: Potential efficacy of therapies targeting
intrahepatic lesions after sorafenib treatment of patients with
hepatocellular carcinoma. BMC Cancer. 31:3382016. View Article : Google Scholar
|
|
25
|
Wada Y, Takami Y, Tateishi M, Ryu T,
Mikagi K and Saitsu H: The efficacy of continued sorafenib
treatment after radiologic confirmation of progressive disease in
patients with advanced hepatocellular carcinoma. PLoS One.
11:e01464562016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fu SR, Zhang YQ, Hu BS, He X, Huang JW,
Zhan MX, Lu LG and Li JP: Sorafenib continuation after first
disease progression could reduce disease flares and provide
survival benefits in patients with hepatocellular carcinoma: A
pilot retrospective study. Asian Pac J Cancer Prev. 15:3151–3156.
2014. View Article : Google Scholar : PubMed/NCBI
|
